Drugdiscovery >> Drugs >> News
3324
Views
title
Breakthrough Therapy designation for AML drug volasertib - drugdiscovery.com


The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia.
Read More >>


Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug - September 19, 2013
Related Articles
5510
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

16131
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

6007
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

8770
Views
Novartis muscle drug gets breakthrough therapy designation Novartis muscle drug gets breakthrough therapy designation
The FDA granted a breakthrough therapy status to Novartis’ newly developed compound- bimagrumab (BYM338), used to treat a life-threatening muscle disease called sporadic inclusion body myositis tha Read More >>

Tags: Novartis, cancer cachexia,sarcopenia, COPD, bimagrumab, BYM338, sporadic inclusion body myositis, muscles, waste away

6114
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

7917
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

5579
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

5469
Views
Priority Review designation for Nexavar Priority Review designation for Nexavar
FDA has granted Priority Review designation for the Bayer HealthCare’s and Onyx Pharmaceuticals’ oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of local Read More >>

Tags: Nexavar, sorafenib, thyroid cancer, advanced, Bayer HealthCare, Onyx Pharmaceuticals, priority review designation, FDA

5222
Views
Two-drug therapy more effective than Enbrel monotherapy in RA Two-drug therapy more effective than Enbrel monotherapy in RA
According to a latest clinical trial, combined therapy of Enbrel (etanercept) and methotrexate in patients with rheumatoid arthritis (RA) is more effective than monotherapy with Enbrel. Read More >>

Tags: enbrel, etanercept, methotrexate, rheumatoid artritis, RA, monotherapy, two-drug therapy, clinical trial

13992
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013